¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º j+>Q#&h9  
~I$}#  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ BED@?:U#h  
8ui=2k(  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) Zz")`hUG  
~07RFR  
1. ICAM-1 $c9=mjwH  
H-a^BZ&iU  
2. interleukin 12(IL-12) x u,htx  
 coAW9=o}  
3. tumor infiltrating lymphocyte +S0u=u65  
pzSqbgfrQ  
4. TCR/CD3 complex ]wf |PU~nr  
QK7e|M  
5. hematopoietin receptor family <(uTst  
bX&e_Pd  
6. individual idiotype(IdI) f !!P  
w`Xg%*]}  
7. integrin #NM JZ  
&CO| Y(+  
8. colony-stimulatory factor (CSF) Z"N(=B  
&%:*\_2s  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ,4yG(O$)  
/.)2d8,  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? Z fqQ {_  
@ AggznA8  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ j88=f#<  
d/4ubf+$k  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠT NIst  
&58 {  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ n5>B LtY  
m}rh|x/?  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) Yu1QcFuy  
,}n=Z   
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ (;C$gnr.C  
-ywX5B  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) :wSJ-\'$  
An/>0 5|  
3. immunoglobulin superfamily (IgSF) j6RJC  
gO9'q='5l  
4. selectin ypgliq(  
)CFk`57U  
5. anti-idiotypic antibody (¦ÁId) j/~VP2R`  
9) jo7,VM  
6. major histocompatibility complex(MHC) 8?A@/  
]"C| qR*  
7. immunotolerance ;tXB46  
\moZ6J  
8. biological reponse modifier(BRM) sWp{Y.  
&qNP?>C!=  
9. immune reponse gene (Ir gene) t) ;   
W]} #\\$z  
10. reshaped antibody (or reconstituted antibody) ZYrKG+fkl  
.L~fFn s/  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© qK<aZ%V  
@=02  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ &uv>'S#%  
Fsnw3/Nr  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? #Y/97_2 xa  
z\X60T  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ #&;m< %  
rdORNlK&  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? VC/R)%@%  
516VQ<?B  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ =4YbVA+(  
zyIza@V(  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? >l7eoj  
43UJ#r F  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ gubb .EY  
8Uj68Jl?  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ M>`?m L  
q$e T!'x  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? dbf^A1HI  
},?-$eyX  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ aRFi0h \  
*Y| lO  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: nOA ,x  
TMnT#ypf<5  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: B`'}&6jr.  
*so6]+)cU  
ÃâÒßѧ -ucz+{  
.#:@cP~v  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© R47I\{  
B1 jH.(  
1. CD8 FvtM~[Q  
];YglHH  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) $S"zxEJJ Y  
J8`1V `$  
3. immunoglobulin fold(Ig fold) ThT.iD[  
gn;nS{A  
4. cadherin (Ca-dependent cell adhesion moleculers) hs -}:^S`  
bOnukbJ  
5. idiotype-anti-idiotypic antibody immune network theory ]8q%bsl+  
&L[8Mju6  
6. HLA class II antigen <+mO$0h"r  
V.E.~<7D\  
7. complementarity-determining region (CDR)  Hsux>+Q  
!Cv<>_N).  
8. perforin(or pore-forming protein ,PFP) Cbf,X[u  
ej??j<]  
9. high affinity IL-2 receptor $D2Ain1  
;#Crh}~  
10. artificial active immunization *SAcH_I2$>  
 # 8-P  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 16d{IGMz  
`zvT5=*-#  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠF0o18k_"  
sjVl/t`l  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 a}+ _Yo(Q  
?),K=E+=U  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ U]R|ej  
K`AW?p^$Y  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ _|2";.1E  
gs2&0rnOy\  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 4 9+}OIX  
n*]x02:LjZ  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? rt4|GVa  
rH9|JEz  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ h: (l+jr  
PeR<FSF ,i  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ?(XX  
A UO0  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ^SES')x  
m~\m"zJ4  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ -1Ki7|0,  
jq]\oY8y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© gcY~_'&u  
m+JG e5fR<  
1. immunoglobulin gene rearrangement N_~Wu  
enO=-#  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) % w/1Uo24  
|kRx[UL  
3. flow cytometry(FCM) Sv[_BP\^h  
SX<>6vH&  
4. carrier effect w[7HY@[  
D"><S<C\C  
5. positive selection of T lymphocytes in thymus b8xfV{3L  
\y+F!;IxL  
6. mouse TH1(Th1) and TH2(Th2) subsets oA^ ]x>  
ZtZV:re=  
7. perforin (pore-forming protein ,PFP) <UHf7:0V  
4zvU"np  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) z[I/ AORl  
j;c ^pLUP  
9. SH-2(src-homology region 2) #hiD Z>nr  
sJ*U Fm{  
10. Ab2¦Â (internal image) dEl3?~  
P bC>v  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 8J@OMW&[l  
s~'C'B?  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? {@`Uf;hPAX  
c35vjYQx0  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? |L#r)$n{1  
tWy<9TF  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠk:yu2dQh  
? v*7!2;  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ]qT r4`.  
`Y$5g~3.  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ.EELR]`y7I  
>dH*FZ:c  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ho=]'MS|  
+=xRr?F  
ÃâÒßѧרҵ£º |1 6v4 R  
'%7]xp  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ jiD8|%}v  
-v2q:x'G#  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? r\D8_S_  
Q2PwO;E.`C  
´«È¾²¡Ñ§×¨Òµ£º 55en D  
>gl<$LQ?X  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ''YjeX  
\C.@ @4{  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ (LPc\\Vv  
eF\C?4  
Ïû»¯×¨Òµ£º <5^(l$IBj  
9D21e(7X  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ v%Xe)D   
p+?WhxG)  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? F4{<;4N0  
g>CQO,s;w  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ Jp0.h8i  
R:p,Hav<q  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© )UUe5H6Hd0  
>c eU!=>  
1. Fas(CD95)/FasL ';F][x5j  
}5U f`pM8  
2. common chain of cytokine receptor xb\:H@92  
j+/*NM_y3  
3 . TCR/CD3 complex l"8YIsir  
.|-y+9IP  
4. negaive selection of thymocytes `Mg "!n`  
W aU_Z/{0  
5. artificial active immune <rs]@J'p  
5c8x: e@  
6. anti-idiotypic N%+M+zEJ  
jEIL(0_H  
7. IgSF W{d/m;<@N  
%b9M\  
8. Integrin `RRORzXoS  
Ok!{2$P8U9  
9. chemokine Sy~1U  
r^)<Jy0|r  
10. B7/CD28 WW=7QC i  
D5x^O2  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© 2_Z6 0]  
O/Vue  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ ~4 ab\hq  
&0ra a  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 65v'/m!ys  
<>TBM^  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ U' Cp3>  
r+Y1m\  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ mD! imq%=  
dq2v[? *R  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ U N/.T   
X9R-GT  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ F+GQl  
PLD!BD  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© bHCd|4e,2  
ctGjqHo  
1. B7/CD28 IWkBq]Y  
7Do)++t  
2. Th1 subset n2E2V<#   
kcle|B  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© V47 Fp  
x{m)I <.:  
4. antibody affinity maturation wZ^/-  
2rxdRg'YLQ  
5. AP-1 f5N~ K>  
aUnm9u r  
6. single chain variable fragment£¨ScFv£© 7Ny>W(8  
UJb7v:^  
7. NK cell receptor gV Gq  
fqcyCu7Ep  
8. Zinkernagel-Doherty phenomenon ;RU)Q)a)  
&c]x;#-y  
9. Ig fold ! M bRI  
H Q2-20  
10. CD40/CD40L * 08LW|:,  
p'H5yg3h  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© sI y  LW  
+G?3j,a\  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 2]@U$E='s  
LcF0:h'  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ PgVM> _nHk  
U*-%V$3+w5  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ V@$B>HeK  
}%VHBkuc  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ D,NjDIG8  
46mu,v  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 5~\W!|j/  
1f}Dza9  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ }b1P!xb!A  
il:+O08_  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ }@x0@sI9  
p}C3<[Nk  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© vwP83b0ov"  
,\Cy'TSz  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© r=s7be  
<}|+2f233+  
1.Co-stimulators (or co-stimulating molecules) UA{A G;  
e\\ I,  
2.NK-kB {uq  
qg+ 8i9Y!  
3.Immunoglobulin superfamily XWK A0  
ni9/7   
4.antigen-presenting cell (APC) N'TL &]  
PE3l2kr  
5.death domain x#'# ~EO-G  
=EFF2M `F  
6.CCR and CXCR 'r3 I/qg*m  
$dq R]'  
7.Lectin (or mitogen) ]5B5J  
1H%LUA  
8.Clusters of differentiation, CD) q0$ }MB6  
_bu, 1EM  
9.B7 family Hcuvu[)T"  
sAWUtJ  
10.Cytotoxic T lymphocyte, CTL) $GEY*uIOa  
G|v{[>tr  
11.IL-15 and IL-15 receptor (IL-15R) ?~hC.5  
B G/M3  
12.MHC restriction Z_Hc":4i  
?(4 =:o  
13.Affinity-chromatography dk# LAm0<  
SVo:%mX  
14.Cyctosprin A, CsA ?x=;?7  
>d&B:  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ymiOtA Z  
*{/BPc0*  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 4DaLmQ2O  
=E,^ +`M  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Z~[c65Nlu  
M<4~ewWJ  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ U@ Y0 z.Y  
+:+q,0~*]  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ,C1}gPQ6<  
%7 7v'Pz1  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 9(V12gn+lk  
a6cq0g[#z  
ÃâÒßѧרҵ£º | U )  
yY_Zq\   
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ bz<f u  
CB]#`|f  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Ii FeO  
)O*\}6:S  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ h fZY5+Z<  
gqJSz}'  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) I7,5ID4pn  
W;!OxOWZJ  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 0h=NbLr|S-  
c&me=WD  
1. ADCC(antibody dependent cell-mediated cytotoxicity) EIQ`?8KSR  
&y_Ya%Z3*e  
2. »·æß¾úËØ(cyclosporin) wX<w)@  
@ >_v/U'  
3. KIR(killer cell inhibitory receptor) |iSd<  
5argw+2s4$  
4. HLDA(human leucocyte differentiation antigen) c@f?0|66M  
 /5M0[C E  
5. Interleukin 18(IL-18) F/ p/&9  
,^wjtA 3j8  
6. ÕûºÏËØ(integrin) m-?hHd O  
8_$[SV$q  
7. Fas/FasL `4IZ4sPi  
f[1 s4Dp3-  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) -So$ f-y  
(E(J}r~E  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) uvG' Kx  
(fNG51h!  
10. Th1/Th2 ~cr##Ff 5  
E)>.2{]C>  
11. »ùÒòÒßÃç(DNAÒßÃç) u~c75Mk_v  
LUaOp "  
12. chemokines and chemokine receptor wE~&Y? ^  
'8w}m8{y  
13. ÃâÒßÄÍÊÜ N =T 0Td  
w`YN#G  
14. ¹²´Ì¼¤·Ö×Ó =0t<:-?.-  
3QI.|;X  
15. ËÀÍö½á¹¹Óò(death domain) [_HY6gr  
8/vGA=  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 0?o<cC1Z  
d%Ls'[Y^_0  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? [CG3&J  
u']}Z% A9`  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠoNhCa>)/  
=f?vpKq40  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î %63s(ekU  
icK$W2<8mg  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ D_q"|D$SB  
G\ z5Ue*  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå yGY:EvH^?  
f"z;'  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ mY[*(a  
D"msD"  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 0`/CoP<U  
+ )n}n5  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ ~8&P*oFC  
a9u2Wlz  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ bkuJN%  
cd|/ 4L 6  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛÌ³ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»